Omar Yossofzai

Omar Yossofzai

Auto-generated profile, based on publicly available information

Omar Yossofzai

Department of Diagnostic Imaging Hospital for Sick Children Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2022 in Epilepsia
Verified
Journal Article
Closed access
OYOmar Yossofzai
Omar Yossofzai
AFAria Fallah
Aria Fallah
CMCassia Maniquis
Cassia Maniquis
SWShelly Wang
Shelly Wang
JRJohn Ragheb
John Ragheb
EWElysa Widjaja
Elysa Widjaja

11 November 2022 in Epilepsia
Verified
Journal Article
Closed access
OYOmar Yossofzai
Omar Yossofzai
SSScellig Stone
Scellig Stone
JMJoseph Madsen
Joseph Madsen
RMRahim Moineddin
Rahim Moineddin
SWShelly Wang
Shelly Wang
EWElysa Widjaja
Elysa Widjaja

22 March 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
EWElysa Widjaja
Elysa Widjaja
LDLindsay Demoe
Lindsay Demoe
OYOmar Yossofzai
Omar Yossofzai
AGAstrid Guttmann
Astrid Guttmann
GTGeorge A. Tomlinson
George A. Tomlinson
BSBeate Sander
Beate Sander
Background and Objectives Improvement in seizure control after epilepsy surgery could lead to lower health care resource use and costs, but it is uncertain whether this could offset the high costs related to surgery. This study aimed to evaluate phase-specific and cumulative long-term health care costs of surgery compared to medical therapy in children with drug-resistant epilepsy from the health care payer perspective. Methods Children who were evaluated for epilepsy surgery and treated with surgery or medical therapy from 2003 to 2018 at the Hospital for Sick Children in Toronto were identified from chart review and linked to their health administrative databases in Ontario, Canada. Inverse probability of treatment weighting with stabilized weights was used to balance the baseline covariates between the 2 groups. Patients were assigned to presurgery, surgery, short-term (first 2 years), intermediate-term (2–5 years), and long-term (>5 years) postsurgery care phases on the basis of treatment trajectory. Phase-specific and cumulative long-term health care costs were evaluated. Costs were converted from Canadian to US dollars year 2018 value. Results There were 372 surgical and 258 medical patients. Costs were higher in surgical than medical patients for presurgery (3 and 39 weeks), surgery, and short-term care phase, and the attributable costs of surgery per 7 patient-days were $1,602 (95% CI $1,438–$1,785), $172 (95% CI $147–$185), $19,819 (95% CI $18,822–$20,932), and $28 (95% CI $22–$32), respectively. Costs were lower in surgical patients for intermediate- and long-term care phase, and the attributable costs were −$72 (95% CI −$124 to −$35) and −$94 (95% CI −$129 to −$63), respectively. In surgical patients, costs were highest for surgery followed by presurgery care phase, with hospitalizations accounting for the highest cost component. In medical patients, costs increased gradually from presurgery to long-term care phase. Cumulative costs were higher for surgical than medical patients in the first 7 years after surgery, but from 8 years on, costs were lower for surgical patients. Discussion This study demonstrated the long-term economic benefits of epilepsy surgery compared to medical therapy for the health care system with the use of real-world data, which would justify the high costs of surgery. The results will support future economic evaluation comparing minimally invasive treatment such as laser therapy to surgery.